OKYO Pharma (NASDAQ: OKYO) CDO buys 30,980 shares at $1.59

Rhea-AI Filing Summary

OKYO Pharma Limited reports that its Chief Development Officer and Director, Gary Jacob, has acquired 30,980 ordinary shares on Nasdaq at $1.59 per share, increasing his holding to 108,920 shares. The company highlights its lead candidate urcosimod, which has shown anti-inflammatory and pain‑reducing effects in preclinical models and positive pain‑reduction data in an 18‑subject Phase 2a neuropathic corneal pain trial and a prior 240‑subject dry eye disease trial. OKYO recently completed a successful Phase 2 trial in neuropathic corneal pain and plans a ~150‑subject Phase 2b/3 multiple‑dose study in the first half of this year.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 19, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: March 19, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated March 19, 2026

4

Exhibit 99.1

 OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

Business Development & Investor Relations Paul Spencer +44 (0)20 7495 2379

-1-

FAQ

What insider share purchase did OKYO (OKYO) disclose in this 6-K?

OKYO Pharma reported that Chief Development Officer and Director Gary Jacob acquired 30,980 ordinary shares on Nasdaq at $1.59 each. This transaction increased his total holding to 108,920 shares, signaling a larger personal stake in the company’s equity.

What is urcosimod and what eye conditions is OKYO (OKYO) targeting?

Urcosimod is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor found on ocular immune and nerve cells. OKYO is developing it for neuropathic corneal pain and inflammatory eye diseases, aiming to reduce pain and inflammation in these difficult-to-treat conditions.

What clinical trial results has OKYO (OKYO) reported for urcosimod in neuropathic corneal pain?

OKYO reported positive neuropathic corneal pain reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 subjects. These results support further development of urcosimod as a potential treatment option for patients suffering from neuropathic corneal pain.

How has urcosimod performed in dry eye disease studies for OKYO (OKYO)?

Urcosimod showed significant pain reduction in a 240-subject Phase 2, multi-center, double-masked, placebo-controlled dry eye disease trial. These findings help justify its development for neuropathic corneal pain, where ocular surface inflammation and nerve-related pain are closely linked.

What future clinical plans does OKYO (OKYO) have for urcosimod?

OKYO plans to initiate a ~150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of this year. This larger trial is intended to further evaluate efficacy and safety in a more advanced development stage.

How does OKYO (OKYO) describe its overall business focus?

OKYO Pharma describes itself as a clinical-stage biopharmaceutical company developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. Its ordinary shares trade on the Nasdaq Capital Market, and urcosimod is its flagship drug candidate in development.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 9.0 KB
• EX-99 GRAPHIC 19.3 KB